Antiarrhythmic Therapy in Special Populations

Introduction to Amiodarone Therapy

Amiodarone can be administered intravenously at a dose of 5 mg/kg over one hour, or over 15 minutes in life-threatening situations, for patients who cannot swallow tablets, as recommended by the British medical guidelines 1
Baseline assessment and regular monitoring of liver transaminase levels are recommended due to the risk of hepatocellular injury and liver enzyme elevation, with consideration of dose reduction for mild-moderate elevation (2-5x baseline) of liver enzymes, as recommended by the American Academy of Family Physicians 2

The following tests should be monitored at the specified frequencies:

Test	Frequency	Comments
Thyroid function tests	Every 6 months	Include TSH, free T4, and T3
Liver function tests	Every 6 months	Include AST and ALT
Digoxin levels	Every 6-12 months	Monitor for increased serum levels
Prothrombin time/INR	Weekly for the first 6 weeks	Monitor for increased anticoagulant effect
Pulmonary function tests	Every 3-6 months	Include diffusion capacity for carbon monoxide (DLCO) and chest imaging
Ophthalmologic examination	Every 6 months	Monitor for corneal microdeposits and optic neuropathy/neuritis

Monitoring is crucial due to amiodarone's potential to inhibit multiple cytochrome P450 pathways, leading to increased toxicity of other medications, including warfarin, digoxin, statins, and beta-blockers and calcium channel blockers, as recommended by the American Academy of Family Physicians and the Journal of the American College of Cardiology 2, 3, 4

Amiodarone is contraindicated in patients with hypersensitivity to amiodarone or iodine, cardiogenic shock, marked sinus bradycardia, and second- or third-degree AV block without a functional pacemaker, as well as pregnancy and lactation due to the potential risk to the fetus or baby, as stated in the Journal of the American College of Cardiology 2, 3

Alternative agents such as sotalol, dronedarone, propafenone, and flecainide can be considered for ventricular arrhythmias and atrial fibrillation, depending on patient characteristics and contraindications, with a strength of evidence level of IIb (low-quality evidence), as noted by the American College of Cardiology 5, 6, 7
A recommended loading dose of amiodarone is 600 mg twice daily for 7 days, followed by a maintenance dose of 400-600 mg daily, which can be reduced to the lowest effective dose (often 200 mg/day), with a strength of evidence level of IIa (moderate-quality evidence), as noted by the American College of Cardiology 2
The American Heart Association recommends a loading dose of 1.2 to 1.8 g/day divided until a total of 10 g is reached, or 30 mg/kg as a single dose for hospitalized patients, and 600 to 800 mg/day divided until a total of 10 g is reached for ambulatory patients, with a maintenance dose of 200 to 400 mg/day, as recommended by the American College of Cardiology and the American Heart Association 8, 9

The European Association for the Study of the Liver and the American Academy of Family Physicians recommend waiting at least 3 months after discontinuing amiodarone before initiating sofosbuvir due to the risk of fatal arrhythmias, with a strength of evidence level of IIb (low-quality evidence) 10, 2, 11
Amiodarone is not considered a first-line treatment for atrial fibrillation due to its numerous potentially severe adverse effects, including pulmonary, thyroid, and hepatic toxicity, despite its high efficacy, as noted by the American College of Cardiology, and the use of low doses (200 mg/day or less) may be effective and associate with fewer side effects, as noted by the American College of Cardiology and the European Society of Cardiology 8, 12